

Treatment with New Class of Drugs Shows Improvement in 20 Dermatological Conditions

NEW YORK, NY, UNITED STATES, July 23, 2024 /EINPresswire.com/ -- Janus Kinase (JAK) inhibitors interfere with the JAK-STAT signaling pathway, which can correct problems of inflammation and immune function. Upadacitinib, a JAK inhibitor, has been increasingly used as a treatment for hard-to-treat inflammatory diseases. The first JAK inhibitor, ruxolitinib, was FDA-approved in



Off-label use of JAK inhibitor Upadacitinib unveils its potential for use in 20 dermatological conditions.”

Shivkar Amara

2011, and now there are a total of nine approved JAK inhibitors for the treatment of rheumatologic, dermatologic, gastrointestinal, neoplastic indications, and COVID-19. Due to their unique safety and effectiveness profiles, the use of JAK inhibitors for various skin problems is rapidly growing.

In this new study in [SKIN: The Journal of Cutaneous](#)

[Medicine](#)[®], Shivkar Amara and his coauthors conducted a review of published literature, examining 941 articles. From these, they selected 50 studies that provided insights into the off-label use of upadacitinib for 20 different dermatologic conditions. Most of these conditions showed improvement by actively decreasing the inflammatory response involved in their development.

Upadacitinib works by blocking Janus Kinase, specifically JAK 1, more than others, reducing side effects. It is approved for the treatment of atopic dermatitis (≥ 12 years), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondylarthritis, ulcerative colitis, and Crohn’s disease. Upadacitinib shows potential promise in treating a number of other challenging inflammatory skin conditions, treatment-resistant itching, and medication-induced skin reactions. There are ongoing clinical trials for use of upadacitinib for other skin issues including hair loss, sweat problems and pigment loss. The authors emphasize that more clinical trials are needed to evaluate the further indications of upadacitinib and its safety profile.

SKIN: The Journal of Cutaneous Medicine[®] is a peer-reviewed online medical journal that is the official journal of The National Society for Cutaneous Medicine. The mission of SKIN is to provide an enhanced and accelerated route to disseminate new dermatologic knowledge for all aspects of cutaneous disease.

For more details, please visit www.jofskin.org or contact jofskin@gmail.com.

Shivkar Amara

Icahn School of Medicine at Mount Sinai

shivkar.amara@mountsinai.org

This press release can be viewed online at: <https://www.einpresswire.com/article/729823898>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.